494762-08-2

Usage

Uses

Used in Pharmaceutical Industry:
(2E)-3-(2-chloro-6-fluorophenyl)-1-(4-chlorophenyl)prop-2-en-1-one is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of diverse classes of compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, (2E)-3-(2-chloro-6-fluorophenyl)-1-(4-chlorophenyl)prop-2-en-1-one serves as a key intermediate in the production of agrochemicals. Its reactivity and structural features enable the creation of compounds that can be used in agricultural applications, such as pesticides or herbicides, to improve crop protection and yield.

Upstream product

• 387-45-1 2-chloro-6-fluorobenzaldehyde 
• 99-91-2 para-chloroacetophenone 

Downstream Products

• 671766-98-6 7-(2-chloro-6-fluorophenyl)-5-(4-chlorophenyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine 
• 1320360-99-3 7-(2-chloro-6-fluorophenyl)-5-(4-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion

The high levels of hepatitis B virus (HBV) surface antigen (HBsAg)-bearing subviral particles in the serum of chronically infected individuals play an important role in suppressing HBV-specific immune response and are only mildly affected by the current small molecule therapies. Thus, a therapy that specifically reduces HBsAg serum levels could be used in combination therapy with nucleos(t)ide drugs or permit therapeutic vaccination for the treatment of HBV infection. Herein, we report the design, synthesis, and evaluation of novel triazolo-pyrimidine inhibitors (1, 3, and 4) of HBsAg cellular secretion, with activity against drug-resistant HBV variants. Extensive SAR led to substantial improvements in the EC50 of the parent compound, 5 (HBF-0259), with the best being 3c, with EC50 = 1.4 ± 0.4 μM, SI ≥ 36. The lead candidates, both 1a (PBHBV-001) and 3c (PBHBV-2-15), were well-tolerated in both normal and HBV-transgenic mice and exhibited acceptable pharmacokinetics and bioavailability in Sprague-Dawley rats.